PerformRx, a division of AmeriHealth Mercy, provides The Next Generation of pharmacy benefit management services through a distinctive approach for Managed Care plans and Payers nationwide with unique expertise in Medicaid and Medicare Part D. PerformRx is headquartered in Philadelphia, Pennsylvania.
Home | Search | Contact Us | Careers | Site Map | Print | Email this Page
  Member Client Provider Consultant PerformRx News  
PerformRx
Mission & Guiding Principles
The PerformRx Difference
AmeriHealth Mercy
What is Medicare Part D?
PerformRx Prescription Drug Plan (PDP)
Residency Program
Careers
Contact Us
 
 

PerformRx

PerformRx was formed in 1999 as a division of the AmeriHealth Mercy Family of Companies. We provide specialized pharmacy benefit management services (PBM) through proactively managing escalating pharmacy costs while focusing on clinical and financial results.

PerformRx provides "The Next Generation" of pharmacy benefit management services through a distinctive approach for Managed Care Plans and Payers nationwide, with unique expertise in Medicaid and Medicare Part D. PerformRx is headquartered in Philadelphia, Pennsylvania.

PerformRx is a mission-driven organization, dedicated to the delivery of quality pharmacy benefits to low-income populations covered by publicly funded programs. This commitment directly reflects the vision of our parent company, AmeriHealth Mercy.

The AmeriHealth Mercy Family of Companies is the largest organization of Medicaid managed care plans in the United States, touching the lives of more than 6.2 million members. With more than 20 years of experience exclusively serving the Medicaid population, AmeriHealth Mercy's core products include management, administrative, pharmacy benefit, care management services and behavioral health care services.

Our Clients' Experience

  • Reduction in Drug Ingredient Cost Trend
    5% - 10%
  • Increase in Audit Recovery
    50% - 100%
  • Increase in Rebate Dollars
    50% - 300%
  • Reduction in Prescription Utilization
    5%- 10%
  • Increase in Generic Drug Utilization
    2% - 6%
  • Improved Clinical Outcomes